GCM
TRML

Ghisallo Capital Management’s Tourmaline Bio TRML Stock Holding History

Ghisallo Capital Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,500
Closed -$203K – 525
2021
Q3 		$203K Buy
1,500
+500
+50% +$68.5K 0.01% 435
2021
Q2 		$147K Buy
+1,000
New +$153K 0.01% 388

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Ghisallo Capital Management's TRML Position: Q4 2021 in Review

Ghisallo Capital Management sold out of Tourmaline Bio (TRML) in Q4 2021, closing a stake of 1,500 shares — an estimated $203K sold.

Ghisallo Capital Management first reported a position in TRML in Q2 2021 and held it in 2 quarters. The position peaked at $203K in Q3 2021. 51 funds tracked by Wall St. Rank hold TRML as of Q4 2021.

  • Ghisallo Capital Management reported no remaining Tourmaline Bio position as of Q4 2021 after selling out during the quarter.
  • Ghisallo Capital Management sold 1,500 Tourmaline Bio shares in Q4 2021, an estimated $203K.
  • Ghisallo Capital Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 2 quarters.
  • Ghisallo Capital Management's Tourmaline Bio position peaked at $203K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2021.

Based on Ghisallo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.